Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.68 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.68 |
| ▸ | HPGD | P15428 | 4/20 | 0.68 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.68 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.68 |
| ▸ | SLC16A3 | O15427 | 1/20 | 0.68 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.68 |
| ▸ | SLC16A1 | P53985 | 1/20 | 0.68 |
| ▸ | KMT2A | Q03164 | 9/20 | 0.63 |
| ▸ | MAPT | P10636 | 8/20 | 0.63 |
| ▸ | MEN1 | O00255 | 8/20 | 0.63 |
| ▸ | ATM | Q13315 | 4/20 | 0.63 |
| ▸ | GAA | P10253 | 1/20 | 0.61 |
| ▸ | MAOB | P27338 | 3/20 | 0.60 |
| ▸ | USP2 | O75604 | 3/20 | 0.60 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.60 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.60 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.60 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.59 |
| ▸ | GLA | P06280 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11860823 | 0.88 | KMT2A (0.71) | ALDH1A1KDM4EHPGDSMN1; SMN2HSD17B10 | |
| SCHEMBL5600184 | 0.88 | TP53 (0.55) | ALDH1A1KDM4EHPGDSMN1; SMN2HSD17B10 | |
| SCHEMBL22601122 | 0.87 | SLC16A3 (0.53) | ALDH1A1KDM4EHPGDSMN1; SMN2HSD17B10 | |
| SCHEMBL22601117 | 0.86 | ALDH1A1 (0.52) | ALDH1A1KDM4EHPGDSMN1; SMN2HSD17B10 | |
| SCHEMBL11863208 | 0.85 | MAPT (0.60) | ALDH1A1KDM4EHPGDSMN1; SMN2HSD17B10 | |
| SCHEMBL10613822 | 0.85 | MAOB (0.72) | ALDH1A1KDM4EHPGDSMN1; SMN2HSD17B10 | |
| SCHEMBL9653525 | 0.84 | KMT2A (0.59) | ALDH1A1KDM4EHPGDSMN1; SMN2HSD17B10 | |
| SCHEMBL9612784 | 0.83 | MAOB (0.71) | ALDH1A1KDM4EHPGDSMN1; SMN2HSD17B10 | |
| SCHEMBL22587972 | 0.83 | SLC16A3 (0.66) | ALDH1A1KDM4EHPGDSMN1; SMN2HSD17B10 | |
| SCHEMBL29775307 | 0.81 | ALDH1A1 (1.00) | ALDH1A1KDM4EHPGDSMN1; SMN2HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-100413882-C | Linear basic compounds having NK-2 antagonistic activity and formulations thereof | MENARINI RICERCHE SPA (IT) | 2008-08-27 | — | — | CN | claimed |
| CN-1578786-A | Linear basic compounds having NK-2 antagonistic activity and formulations thereof | MENARINI RICERCHE SPA (IT) | 2005-02-09 | — | — | CN | claimed |
| US-20040259930-A1 | Linear basic compounds having nk-2 antagonist activity and formulations thereof | MALESCI INSTITUTO FARMACOBIOLOGICO S.P.A. (IT) | 2004-12-23 | — | — | US | claimed |
| US-12357603-B2 | Acyl sulfonamides for treating cancer | BAYER AKTIENGESELLSCHAFT (DE) | 2025-07-15 | — | — | US | disclosed |
| EP-3959202-B1 | ACYL SULFONAMIDES FOR TREATING CANCER | BAYER AG (DE) | 2023-08-16 | — | — | EP | disclosed |
| EP-3959202-B1 | ACYL SULFONAMIDES FOR TREATING CANCER | BAYER AG (DE) | 2023-08-16 | — | — | EP | disclosed |
| US-20220226279-A1 | ACYL SULFONAMIDES FOR TREATING CANCER | THE BROAD INSTITUTE, INC. | 2022-07-21 | — | — | US | disclosed |
| CN-114072394-A | Acylsulfonamides for the treatment of cancer | 拜耳股份公司 | 2022-02-18 | — | — | CN | disclosed |
| WO-2020216701-A1 | ACYL SULFONAMIDES FOR TREATING CANCER | BAYER AKTIENGESELLSCHAFT (DE) | 2020-10-29 | — | — | WO | disclosed |
| WO-2020216701-A1 | ACYL SULFONAMIDES FOR TREATING CANCER | BAYER AKTIENGESELLSCHAFT (DE) | 2020-10-29 | — | — | WO | disclosed |
| CN-100413882-C | Linear basic compounds having NK-2 antagonistic activity and formulations thereof | MENARINI RICERCHE SPA (IT) | 2008-08-27 | — | — | CN | disclosed |
| US-7273856-B2 | Linear basic compounds having NK-2 antagonist activity and formulations thereof | MENARINI RICERCHE S.P.A. (IT) | 2007-09-25 | — | — | US | disclosed |
| EP-1442050-B1 | LINEAR BASIC COMPOUNDS HAVING NK-2 ANTAGONIST ACTIVITY AND FORMULATIONS THEREOF | MALESCI SAS (IT) | 2006-09-13 | — | — | EP | disclosed |
| CN-1578786-A | Linear basic compounds having NK-2 antagonistic activity and formulations thereof | MENARINI RICERCHE SPA (IT) | 2005-02-09 | — | — | CN | disclosed |
| US-20040259930-A1 | Linear basic compounds having nk-2 antagonist activity and formulations thereof | MALESCI INSTITUTO FARMACOBIOLOGICO S.P.A. (IT) | 2004-12-23 | — | — | US | disclosed |
| US-3932446-A | Quaternized 6-diethylamino-2-[benzimidazolyl-(2)]benzofuran | BASF AKTIENGESELLSCHAFT (DT) | 1976-01-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220226279-A1 | ACYL SULFONAMIDES FOR TREATING CANCER | KAT6A, KAT6B, KAT2A | ALDH1A1 1645/4885KDM4E 461/4885HPGD 3400/4885 |
| US-12357603-B2 | Acyl sulfonamides for treating cancer | KAT6A, KAT6B, KAT2A | ALDH1A1 1645/4885KDM4E 461/4885HPGD 3400/4885 |
| US-20040259930-A1 | Linear basic compounds having nk-2 antagonist activity and formulations thereof | BDKRB2, BDKRB1, TACR2 | ALDH1A1 2231/4885KDM4E 3285/4885HPGD 1312/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.